Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients.
Urup T, Staunstrup LM, Michaelsen SR, Vitting-Seerup K, Bennedbæk M, Toft A, Olsen LR, Jønson L, Issazadeh-Navikas S, Broholm H, Hamerlik P, Poulsen HS, Lassen U. Urup T, et al. Among authors: hamerlik p. BMC Cancer. 2017 Apr 18;17(1):278. doi: 10.1186/s12885-017-3251-3. BMC Cancer. 2017. PMID: 28420326 Free PMC article.
Preferential Iron Trafficking Characterizes Glioblastoma Stem-like Cells.
Schonberg DL, Miller TE, Wu Q, Flavahan WA, Das NK, Hale JS, Hubert CG, Mack SC, Jarrar AM, Karl RT, Rosager AM, Nixon AM, Tesar PJ, Hamerlik P, Kristensen BW, Horbinski C, Connor JR, Fox PL, Lathia JD, Rich JN. Schonberg DL, et al. Among authors: hamerlik p. Cancer Cell. 2015 Oct 12;28(4):441-455. doi: 10.1016/j.ccell.2015.09.002. Cancer Cell. 2015. PMID: 26461092 Free PMC article.
Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines.
Jandu H, Aluzaite K, Fogh L, Thrane SW, Noer JB, Proszek J, Do KN, Hansen SN, Damsgaard B, Nielsen SL, Stougaard M, Knudsen BR, Moreira J, Hamerlik P, Gajjar M, Smid M, Martens J, Foekens J, Pommier Y, Brünner N, Schrohl AS, Stenvang J. Jandu H, et al. Among authors: hamerlik p. BMC Cancer. 2016 Jan 22;16:34. doi: 10.1186/s12885-016-2071-1. BMC Cancer. 2016. PMID: 26801902 Free PMC article.
Combined EGFR- and notch inhibition display additive inhibitory effect on glioblastoma cell viability and glioblastoma-induced endothelial cell sprouting in vitro.
Staberg M, Michaelsen SR, Olsen LS, Nedergaard MK, Villingshøj M, Stockhausen MT, Hamerlik P, Poulsen HS. Staberg M, et al. Among authors: hamerlik p. Cancer Cell Int. 2016 Apr 26;16:34. doi: 10.1186/s12935-016-0309-2. eCollection 2016. Cancer Cell Int. 2016. PMID: 27118928 Free PMC article.
Macropinocytosis of Bevacizumab by Glioblastoma Cells in the Perivascular Niche Affects their Survival.
Müller-Greven G, Carlin CR, Burgett ME, Ahluwalia MS, Lauko A, Nowacki AS, Herting CJ, Qadan MA, Bredel M, Toms SA, Lathia JD, Hambardzumyan D, Sarkaria JN, Hamerlik P, Gladson CL. Müller-Greven G, et al. Among authors: hamerlik p. Clin Cancer Res. 2017 Nov 15;23(22):7059-7071. doi: 10.1158/1078-0432.CCR-17-0249. Epub 2017 Sep 14. Clin Cancer Res. 2017. PMID: 28912141 Free PMC article.
VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance.
Michaelsen SR, Staberg M, Pedersen H, Jensen KE, Majewski W, Broholm H, Nedergaard MK, Meulengracht C, Urup T, Villingshøj M, Lukacova S, Skjøth-Rasmussen J, Brennum J, Kjær A, Lassen U, Stockhausen MT, Poulsen HS, Hamerlik P. Michaelsen SR, et al. Among authors: hamerlik p. Neuro Oncol. 2018 Oct 9;20(11):1462-1474. doi: 10.1093/neuonc/noy103. Neuro Oncol. 2018. PMID: 29939339 Free PMC article.
VEGF-C as a putative therapeutic target in cancer.
Michaelsen SR, Poulsen HS, Hamerlik P. Michaelsen SR, et al. Among authors: hamerlik p. Oncotarget. 2019 Jun 18;10(40):3988-3990. doi: 10.18632/oncotarget.27007. eCollection 2019 Jun 18. Oncotarget. 2019. PMID: 31258839 Free PMC article. No abstract available.
53 results